Literature DB >> 18237684

The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study.

Leonarda Galiuto1, Barbara Garramone, Antonio Scarà, Antonio G Rebuzzi, Filippo Crea, Giuseppe La Torre, Stefania Funaro, Mariapina Madonna, Francesco Fedele, Luciano Agati.   

Abstract

OBJECTIVES: We sought to evaluate the value of the extent of microvascular damage as assessed with myocardial contrast echocardiography (MCE) in the prediction of left ventricular (LV) remodeling after ST-segment elevation myocardial infarction (STEMI) as compared with established clinical and angiographic parameters of reperfusion.
BACKGROUND: Early identification of post-percutaneous coronary intervention microvascular dysfunction may help in tailoring appropriate pharmacological interventions in high-risk patients. The ideal method to establish effective microvascular reperfusion after percutaneous coronary intervention remains to be determined.
METHODS: A total of 110 patients with first successfully reperfused STEMI were enrolled in the AMICI (Acute Myocardial Infarction Contrast Imaging) multicenter study. After reperfusion, peak creatine kinase, ST-segment reduction, and Thrombolysis In Myocardial Infarction (TIMI) and myocardial blush grade were calculated. We evaluated perfusion defects with MCE by using continuous infusion of Sonovue (Bracco, Milan, Italy) in real-time imaging. The endocardial length of contrast defect (CD) on day 1 after reperfusion was calculated. Wall motion score index, the extent of wall motion abnormalities, LV end-diastolic volume, and ejection fraction after reperfusion and at follow-up also were calculated.
RESULTS: Of 110 patients, 25% evolved in LV remodeling and 75% did not. Although peak creatine kinase, ST-segment reduction >70%, and myocardial blush grade were not different between groups, in patients exhibiting LV remodeling, TIMI flow grade 3 was less frequent (p < 0.001), wall motion score index was greater (p < 0.001), and CD was greater (p < 0.001). At multivariate analysis, only TIMI flow grade <3 and CD with a cutoff of >25% were independently associated with LV remodeling. Among patients with TIMI flow grade 3, CD was the only independent variable associated with LV remodeling.
CONCLUSIONS: Among patients with TIMI flow grade 3, the extent of microvascular damage, detected and quantitated by MCE, is the most powerful independent predictor of LV remodeling after STEMI as compared with persistent ST-segment elevation and myocardial blush grade.

Entities:  

Mesh:

Year:  2008        PMID: 18237684     DOI: 10.1016/j.jacc.2007.09.051

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  43 in total

1.  Vessel masking improves densitometric myocardial perfusion assessment.

Authors:  Tamás Ungi; Zsolt Zimmermann; Erika Balázs; András Lassó; Imre Ungi; Tamás Forster; András Palkó; Attila Nemes
Journal:  Int J Cardiovasc Imaging       Date:  2008-10-04       Impact factor: 2.357

Review 2.  Non-invasive imaging of microvascular damage.

Authors:  L Galiuto; L Natale; L Leccisotti; G Locorotondo; A Giordano; L Bonomo; F Crea
Journal:  J Nucl Cardiol       Date:  2009-08-25       Impact factor: 5.952

3.  Is cardiac magnetic resonance necessary for prediction of left ventricular remodeling in patients with reperfused ST-segment elevation myocardial infarction?

Authors:  Eun Kyoung Kim; Young Bin Song; Sung-A Chang; Sung-Ji Park; Joo-Yong Hahn; Seung Hyuk Choi; Jin-Ho Choi; Hyeon-Cheol Gwon; Seung-Woo Park; Yeon Hyeon Choe; Joonghyun Ahn; Keumhee Carriere; Sang-Chol Lee
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-28       Impact factor: 2.357

Review 4.  Contrast echocardiography for detection of myocardial perfusion abnormalities : A clinical perspective.

Authors:  N Karogiannis; R Senior
Journal:  Herz       Date:  2017-05       Impact factor: 1.443

5.  The role of cardiac magnetic resonance imaging following acute myocardial infarction.

Authors:  Dennis T L Wong; James D Richardson; Rishi Puri; Adam J Nelson; Angela G Bertaso; Karen S L Teo; Matthew I Worthley; Stephen G Worthley
Journal:  Eur Radiol       Date:  2012-03-25       Impact factor: 5.315

6.  Quantitative myocardial blush score (QuBE) allows the prediction of heart failure development in long-term follow-up in patients with ST-segment elevation myocardial infarction: Proof of concept study.

Authors:  Andrzej Tomasik; Tomasz Młyńczak; Edyta Nowak; Katarzyna Pigoń; Artur Iwasieczko; Mariusz Opara; Ewa Nowalany-Kozielska
Journal:  Cardiol J       Date:  2017-11-13       Impact factor: 2.737

Review 7.  Coronary microvascular dysfunction: mechanisms and functional assessment.

Authors:  Paolo G Camici; Giulia d'Amati; Ornella Rimoldi
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 8.  A role for pericytes in coronary no-reflow.

Authors:  Fergus M O'Farrell; David Attwell
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 32.419

9.  Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction.

Authors:  Alexandre A Cochet; Luc Lorgis; Alain Lalande; Marianne Zeller; Jean-Claude Beer; Paul M Walker; Claude Touzery; Jean-Eric Wolf; François Brunotte; Yves Cottin
Journal:  Eur Radiol       Date:  2009-04-07       Impact factor: 5.315

10.  Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study.

Authors:  Stefania Funaro; Giuseppe La Torre; Mariapina Madonna; Leonarda Galiuto; Antonio Scarà; Alessandra Labbadia; Emanuele Canali; Antonella Mattatelli; Francesco Fedele; Francesco Alessandrini; Filippo Crea; Luciano Agati
Journal:  Eur Heart J       Date:  2008-12-18       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.